JUNS JUPITER NEUROSC

-

JUPITER NEUROSC Reported Earnings

Friday, August 14, 2026 · 12:00 AM ET

JUPITER NEUROSC (JUNS) reported a loss of $5.06 per share on revenue of $0.02 million for the . .

Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia and MELAS. Jupiter Neurosciences Inc. is based in Jupiter, Florida.

Earnings Whisper Grade
Power Rating
Reported Earnings
($5.06)
Earnings Whisper®
Consensus Estimate
Earnings Surprise
Earnings Growth3.6 %
Reported Revenue
$0.02M
Revenue Estimate
Revenue Surprise
Revenue Growth